This article is more than 5 years old. Information may no longer be current.

Levothyroxine sodium shortage announced with no resolution date

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The American Thyroid Association has acknowledged a shortage of levothyroxine sodium, according to a statement on their website.

“We have been informed that this is a temporary shortage due to packaging related issues, but no resolution date has been stated,” the acknowledgment said.

The ATA has reported they will monitor the situation and provide further information regarding the shortage of Levoxyl (Pfizer) as it becomes available.

In a letter to health care providers and pharmacists, the manufacturer wrote they have halted shipping all strengths of the product as of February 13, 2013 and the backorder situation is currently being discussed with the FDA.

“It is important to note that Pfizer cannot make any recommendations regarding an alternative and/or substitute therapy for Levoxyl. A change in therapy will be at the prescriber’s discretion,” the manufacturer wrote.

Health care providers and pharmacists are advised to call 1-800-438-1985 for medically-related questions about the drug.

For more information:

American Thyroid Association announcement. Accessed March 21, 2013.

Pfizer Customer Letter. Accessed March 21, 2013.